Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia

Advances in Therapy

Volumn 25, Issue 11, 2008, Pages 1215-1228

  Baldamus, Conrad ^a   Krivoshiev, Stefan ^b   Wolf Pflugmann, Michael ^c   Siebert Weigel, Marianne ^c   Koytchev, Rossen ^d   Bronn, Angelika ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Multidisciplinary Hospital for Active Treatment Queen Giovanna Ltd   (Bulgaria)

^c STADA R and D GmbH   (Germany)

^d CCDRD AG   (Germany)

Author keywords

Efficacy; Epoetin zeta; Erythropoietin; Long term safety; Maintenance treatment; Renal anemia

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RENAL REPLACEMENT THERAPY;

ANEMIA; BLOOD TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS;

EID: 69949150756     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0111-1     Document Type: Article

References (29)

1. Ridley DM, Dawkins F, Perlin E. Erythropoietin: a review. J Natl Med Assoc. 1994;86:129-135.
2. Wang GL, Semenza GL. Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol. 1996;3:156-162. (Pubitemid 26178055)
3. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant. 1999;14:22-28. (Pubitemid 29154936)
4. Erypo/Erypo Product information. Neuss, Germany: JANSSEN-CILAG GmbH Germany; 2002.
5. Levin A. Identifcation of patients and risk factors in chronic kidney disease-evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant. 2001;16:57-60. (Pubitemid 33062125)
6. Tarif N. Anemia management in patients with chronic renal disease: current recommendations. Saudi J Kidney Dis Transpl. 2002;13:331-335.
7. Macdougall IC. Treatment of renal anemia with recombinant human erythropoietin. Curr Opin Nephrol Hypertens. 1992;1:210-219.
8. Gregory N. Quality of life in patients on dialysis: benefts of maintaining a hemoglobin of 11 to 12 g/dL. Nephrol Nurs J. 2005;32:307-310.
9. Popovsky MA, Ransil BJ. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematol. 1996;12:1-3. (Pubitemid 26102951)
10. Tsakiris D. Morbidity and mortality reduction associated with the use of erythropoietin. Nephron. 2000;85 (suppl. 1):2-8. (Pubitemid 30192921)
11. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10:1309-1316. (Pubitemid 29246997)
12. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products. CHMP/437/04. London: EMEA; October 2005. Available at: www.emea.europa.eu/pdfs/human/biosimilar/ 043704en.pdf. Accessed September 2, 2008.
13. European Medicines Agency. Committee for Medicinal Products for Human Use. Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-clinical and Clinical Issues: Guidance on Similar Medicinal Products Containing Recombinant Erythropoietins. EMEA/CHMP/BMWP/94526/2005 Corr. London: EMEA; March 2006. Available at: www.emea.europa.eu/pdfs/human/biosimilar/9452605en.pdf. Accessed September 2, 2008.
14. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. The epoetin zeta study group. Comparison of the therapeutic Effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24: 625-637. (Pubitemid 351428973)
15. Krivoshiev S, Todorov V, Manitius J, Czekalski S, Scigalla P, Koytchev R. Epoetin Zeta Study Group. Comparison of the therapeutic Effects of epoetin zeta and epoetin alfa in the correction of renal anemia. Curr Med Res Opin. 2008;24:1407-1415. (Pubitemid 351741574)
16. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. World Medical Association web site. Available at: www.wma.net/e/policy/b3.htm. Accessed September 2, 2008.
17. "Note of Clarifcation on Paragraph 29" added by the World Medical Association General Assembly, Washington 2002. World Medical Association web site. Available at: www.wma.net/e/policy/b3.htm. Accessed September 2, 2008.
18. ICH Topic E 6. Guideline for Good Clinical Practice. Step 5, Consolidated Guideline from 01.05.1996. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). Woden, Australia: TGA; 2000. Available at: www.tga.gov.au/docs/pdf/euguide/ich/ich13595.pdf. Accessed September 2, 2008.
19. Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl. 2):1-47.
20. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Terapeutic Proteins. CHMP/14327/06. London: EMEA; December 2007. Available at: www.emea.europa.eu/pdfs/human/biosimilar/1432706enfn.pdf. Accessed September 2, 2008.
21. Tacey R, Greyway A, Smiell J, et al. The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Meth. 2003;283:317-329. (Pubitemid 37501079)
22. Casadevall N. Epoetin-induced autoimmune pure red cell aplasia. Hematol J. 2004;5(suppl. 3):104-109.
23. Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73:389-396. (Pubitemid 39571711)
24. Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med. 1998;339;625-627. (Pubitemid 28385662)
25. Eprex Product information. Toronto, ON: Janssen-Ortho CA Inc.; 2006.
26. NeoRecormon Product information. Welwyn Garden City, Hertfordshire: Roche Registration Ltd.; 2002.
27. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003,64:1514-1521. (Pubitemid 37153820)
28. Eschbach J W, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000. (Pubitemid 20034923)
29. Samtleben W, Ehmer B, Lutz-Knochenhauer I, Hagmann C, Scigalla P, Gurland HJ. Side Effects during recombinant human erythropoietin therapy in 2000 ESRD patients. Contrib Nephrol. 1991;88:107-116.